{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:11Z","timestamp":1793406851837,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74556-5","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:02:27Z","timestamp":1727931747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans"],"prefix":"10.1038","volume":"14","author":[{"given":"Toshio","family":"Ichiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"74556_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers11070984","volume":"11","author":"G Al-Khadairi","year":"2019","unstructured":"Al-Khadairi, G. & Decock, J. Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME? Cancers (Basel). 11, 984 (2019).","journal-title":"Cancers (Basel)"},{"key":"74556_CR2","first-page":"73","volume":"9","author":"K Ding","year":"2012","unstructured":"Ding, K. et al. PRAME gene expression in acute leukemia and its clinical significance. Cancer Biol. Med.9, 73\u201376 (2012).","journal-title":"Cancer Biol. Med."},{"key":"74556_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","volume":"109","author":"P Doolan","year":"2008","unstructured":"Doolan, P. et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res. Treat.109, 359\u2013365 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"74556_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00428-023-03629-z","volume":"483","author":"A \u0160afanda","year":"2023","unstructured":"\u0160afanda, A. et al. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. Virchows Arch.483, 509\u2013516 (2023).","journal-title":"Virchows Arch."},{"key":"74556_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00428-023-03606-6","volume":"483","author":"C Cammareri","year":"2023","unstructured":"Cammareri, C. et al. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications. Virchows Arch.483, 145\u2013156 (2023).","journal-title":"Virchows Arch."},{"key":"74556_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/00000478-200604000-00002","volume":"30","author":"JJ Abbott","year":"2006","unstructured":"Abbott, J. J., Oliveira, A. M. & Nascimento, A. G. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am. J. Surg. Pathol.30, 436\u2013443 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"74556_CR7","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/ijms25031582","volume":"25","author":"F Cassalia","year":"2024","unstructured":"Cassalia, F. et al. PRAME updated: Diagnostic, prognostic, and therapeutic role in skin cancer. Int. J. Mol. Sci.25, 1582 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"74556_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/biolre\/ioab074","volume":"105","author":"CH Kern","year":"2021","unstructured":"Kern, C. H., Yang, M. & Liu, W. S. The PRAME family of cancer testis antigens is essential for germline development and gametogenesis. Biol. Reprod.105, 290\u2013304 (2021).","journal-title":"Biol. Reprod."},{"key":"74556_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.oraloncology.2012.08.005","volume":"49","author":"MJ Szczepanski","year":"2013","unstructured":"Szczepanski, M. J. et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol.49, 144\u2013151 (2013).","journal-title":"Oral Oncol."},{"key":"74556_CR10","doi-asserted-by":"publisher","first-page":"154543","DOI":"10.1016\/j.prp.2023.154543","volume":"247","author":"G Broggi","year":"2023","unstructured":"Broggi, G. et al. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: a clinico-pathologic and immunohistochemical study on a series of 85 cases. Pathol. Res. Pract.247, 154543 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"74556_CR11","first-page":"954","volume":"119","author":"T Passeron","year":"2009","unstructured":"Passeron, T. et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J. Clin. Invest.119, 954\u2013963 (2009).","journal-title":"J. Clin. Invest."},{"key":"74556_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.canlet.2017.06.015","volume":"403","author":"YK Lee","year":"2017","unstructured":"Lee, Y. K. et al. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer Lett.403, 144\u2013151 (2017).","journal-title":"Cancer Lett."},{"key":"74556_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping, M. T. et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 122, 835\u2013847 (2005).","journal-title":"Cell"},{"key":"74556_CR14","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ejso.2017.03.011","volume":"43","author":"P Rutkowski","year":"2017","unstructured":"Rutkowski, P. et al. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - the impact of fibrosarcomatous transformation. Eur. J. Surg. Oncol.43, 1134\u20131141 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"key":"74556_CR15","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep.7, 16878 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74556-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74556-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74556-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:05:43Z","timestamp":1727931943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74556-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74556"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74556-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4275491\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles embodied in the Declaration of Helsinki. This study was also approved by the Ethics Committee of Kyushu University (Nos. 29\u2013625, 29\u2013429, 2020\u2009\u2212\u2009361, 2021\u2009\u2212\u2009165). Written informed consent was obtained from each patient before his\/her enrollment to the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no significant relationships with, or financial interest in, any commercial entities pertaining to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22973"}}